TRANSCODE THERAPEUTICS INC (RNAZ)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.06-4.19%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RNAZ
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Progress clinical trials of TTX-MC138, including Phase 1a completion and Phase 2a initiation targeting metastatic and micrometastatic cancers.
Stated as a priority in 2 recent disclosures including 2026-Q2. The Phase 1a clinical trial treated 16 patients with 86 doses, showing no dose-limiting toxicities and 64% stable disease rate over six months. Management is advancing to Phase 2a trials targeting ctDNA-positive colorectal cancer. The trajectory shows delivering on clinical development milestones with ongoing patient treatment and trial progression.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Phase 1a trial met primary endpoint of safety with no dose-limiting toxicities; advancing to Phase 2a clinical development.”
“Phase 1a dose escalation completed; recommended Phase 2a dose selected; Phase 2a trial initiated.”
Continue managing capital allocation through acquisitions, equity financing agreements, and addressing shareholder rights.
Management stated capital allocation priorities in 4 quarters including 2025-Q3 through 2026-Q2. Actions include a $14 million equity purchase agreement in 2026-Q1, acquisition of a pre-clinical program in 2025-Q4, and modifications to securityholder rights in 2026-Q2. These activities show ongoing management of capital resources with mixed financial results given continued operating losses.
“Material Modification to Rights of Securityholders announced.”
“Entered Standby Equity Purchase Agreement with Yorkville for up to $14 million.”
“Acquisition completed of pre-clinical candidate program involving genetically-engineered adenoviruses.”
“Unregistered sales of equity securities disclosed.”
Respond to Nasdaq deficiency notices and manage legal and regulatory risks including litigation and listing compliance.
Management addressed Nasdaq listing compliance and regulatory challenges in 3 quarters including 2025-Q4 through 2026-Q2. The company received deficiency notices for minimum stockholders’ equity and faced litigation related to the Annual Meeting and clinical trial disclosures. Financials show ongoing net losses and negative operating income, indicating regulatory and financial challenges remain unresolved.
“Litigation filed related to Annual Meeting and clinical trial disclosures.”
“Received Nasdaq deficiency letter for minimum stockholders’ equity requirement.”
“Further litigation filed related to clinical trial results and disclosures.”
Over the trailing year it converted 0.47x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
30 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.